Rahman M Z, Ahmed D S, Masud H, Parveen S, Rahman M A, Chowdhury M S, Barua R, Ishaque S M
Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka.
Bangladesh Med Res Counc Bull. 2013 Apr;39(1):11-3. doi: 10.3329/bmrcb.v39i1.15791.
Peginterferon alpha-2a and ribavirin combination therapy achieves a sustained virological response (SVR) in patients with chronic hepatitis C. Little is know about long-term durability of hepatitis C virus--Ribonucleic acid (HCV-RNA) negativity in patient treated with pegylated interferon and ribavirin therapy. Aim of this study was to evaluate the durability of virologic response in patients with SVR to anti-viral therapy treated at our centre. A total of 52 patients with chronic hepatitis C virus infection who had obtained SVR after Peginterferon alpha-2a and ribavirin combination therapy were followed up to 5 years with annual HCV-RNA testing. During this follow up period, 4 of 52 patients with initial SVR developed late relapse of hepatitis C virus infection. Relapse was more common in patients who has cirrhosis (3/6 [50%]) vs (1/46 [2.17%]) without cirrhosis. In conclusion, SVR is durable in most patients, but some patients do have late relapse; long-term follow up may be particularly important in a subset of patients with hepatitis C virus infection who have liver cirrhosis.
聚乙二醇化干扰素α-2a与利巴韦林联合治疗可使慢性丙型肝炎患者获得持续病毒学应答（SVR）。对于接受聚乙二醇化干扰素和利巴韦林治疗的患者，丙型肝炎病毒核糖核酸（HCV-RNA）阴性的长期持久性知之甚少。本研究的目的是评估在我们中心接受抗病毒治疗获得SVR的患者病毒学应答的持久性。共有52例慢性丙型肝炎病毒感染患者在接受聚乙二醇化干扰素α-2a与利巴韦林联合治疗后获得SVR，并通过每年检测HCV-RNA进行了长达5年的随访。在该随访期间，52例初始获得SVR的患者中有4例出现了丙型肝炎病毒感染的晚期复发。肝硬化患者的复发更为常见（3/6 [50%]），而无肝硬化患者为（1/46 [2.17%]）。总之，大多数患者的SVR是持久的，但一些患者确实会出现晚期复发；对于丙型肝炎病毒感染且患有肝硬化的部分患者，长期随访可能尤为重要。
